Everyone who follows the drug-pricing controversy already knows the exploits, if not the name, of Martin Shkreli.
He's the CEO whose company, Turing Pharmaceuticals, acquired the rights to a drug that's crucial for some HIV and cancer patients and promptly jacked up its price by 5,000%, to $750 per pill from $13.50. (We covered the episode here.)
The action didn't make him a very popular figure in the patient advocacy community. Now it turns out that he's not so popular among some biotech investors, either.